LEONID METELITSA to Receptors, Antigen, T-Cell
This is a "connection" page, showing publications LEONID METELITSA has written about Receptors, Antigen, T-Cell.
Connection Strength
0.920
-
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest. 2009 Jun; 119(6):1524-36.
Score: 0.218
-
Refining chimeric antigen receptors via barcoded protein domain combination pooled screening. Mol Ther. 2023 11 01; 31(11):3210-3224.
Score: 0.147
-
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020 11; 26(11):1686-1690.
Score: 0.120
-
A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor. Cancer Immunol Res. 2020 01; 8(1):57-69.
Score: 0.113
-
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma. Clin Cancer Res. 2019 12 01; 25(23):7126-7138.
Score: 0.111
-
Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Hum Gene Ther. 2017 05; 28(5):437-448.
Score: 0.090
-
Distinct homeostatic requirements of CD4+ and CD4- subsets of Valpha24-invariant natural killer T cells in humans. Blood. 2004 Dec 15; 104(13):4150-6.
Score: 0.039
-
Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol. 2001 Sep 15; 167(6):3114-22.
Score: 0.032
-
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res. 2019 03; 7(3):363-375.
Score: 0.027
-
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247.
Score: 0.024